William Dowon Kim

William Dowon Kim

Auto-generated profile, based on publicly available information

William Dowon Kim

Chung-Ang University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2022 in Cancers
Verified
Journal Article
Open access
PDF file
SLSeon-Hwa Lee
Seon-Hwa Lee
ICIksung Cho
Iksung Cho
SYSeng Chan You
Seng Chan You
MCMin-Jae Cha
Min-Jae Cha
JCJeesuk Chang
Jeesuk Chang
HKHyo Song Kim
Hyo Song Kim
Backgrounds: There are scarce data on whether immune checkpoint inhibitors (ICIs) increase the risk of cardiac dysfunction when used with cardiotoxic agents. Thus, we evaluated cardiac dysfunction in patients with sarcoma receiving doxorubicin with or without ICI using echocardiography and left ventricular global longitudinal strain (LVGLS). Methods: A total of 95 patients were included in this study. Echocardiography and LVGLS were evaluated at baseline and follow-up (at 3 and 6 months of chemotherapy) and compared with the doxorubicin (Dox; n = 73) and concomitant ICI with doxorubicin (Dox-ICI; n = 22) groups. Cancer therapy-related cardiac dysfunction (CTRCD) was defined as a left ventricular ejection fraction (LVEF) drop of >10% and LVEF of 10%, LVEF of ≥50%, and LVGLS relative reduction of >15% (probable CTRCD) at six months. Results: There were no significant differences in age, cumulative dose of doxorubicin, and cardiovascular risk factors between the two groups. At baseline, the LVEF was similar in the Dox and Dox-ICI groups (p = 0.493). In the Dox group, LVEF decreased to 59 ± 6% (Δ −7 ± 1.3%, p < 0.001) and LVGLS decreased from −17.3 ± 3.2% to −15.4 ± 3.2% (Δ −10.1 ± −1.9%, p < 0.001) at six months. In the Dox-ICI group, LVEF decreased to 55 ± 9% (Δ −9 ± 2.1%, p < 0.001), along with a significant decrease in LVGLS (from −18.6 ± 1.9% to −15.3 ± 3.6%, Δ −12.4 ± −2.4%, p < 0.001). Over a median follow-up of 192 days, there were no cases with clinical manifestations of fulminant myocarditis. In the Dox group, definite and probable CTRCD were observed in seven (10.1%) and five (7.4%) patients, respectively. In the Dox-ICI group, definite and probable CTRCD were observed in four (19%) and four (19%) patients, respectively. The total number of patients who developed CTRCD was significantly higher in the Dox-ICI group than in the Dox group (38.1% vs. 17.4%, p = 0.042). Serum troponin-T level was significantly higher in the Dox-ICI group than in the Dox group (53.3 vs. 27.5 pg/mL, p = 0.023). Conclusions: ICIs may increase the risk of CTRCD when used with cardiotoxic agents. CTRCD should be monitored in patients treated with ICIs by cardiac biomarkers and echocardiography, including LV-GLS.

15 September 2022 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
MCMin Jae Cha
Min Jae Cha
WKWilliam D Kim
William D Kim
HWHoyoun Won
Hoyoun Won
JJJaeeun Joo
Jaeeun Joo
HKHasung Kim
Hasung Kim
ICIksung Cho
Iksung Cho
Korean Circulation Journal 대한심장학회지 순환기 Cha MJ, et al. Korean Circ J. 2022 Sep;52:e91. https://doi.org/10.4070/kcj.2022.0110

15 August 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
JJJinhwan Jo
Jinhwan Jo
MCMin Jae Cha
Min Jae Cha
HLHee Jeong Lee
Hee Jeong Lee
WKWilliam D. Kim
William D. Kim
JKJinseob Kim
Jinseob Kim
ICIksung Cho
Iksung Cho
Background: Real‐world evidence for the selection of gatekeeping studies in patients with suspected coronary syndromes is limited. Methods and Results: We identified 27 036 patients who underwent coronary computed tomography angiography (CCTA), single‐photon emission computed tomography, and the treadmill test for suspected coronary syndromes from the Korean National Health Insurance Service–National Sample Cohort between 2006 and 2014. The primary end point was a composite of cardiac death and myocardial infarction, and the secondary end point was a composite of the primary end point and revascularization. During a median follow‐up of 5.4 years, the risk of both primary and secondary end points was significantly higher in the single‐photon emission computed tomography group (hazard ratio [HR], 1.81 [95% CI, 1.34–2.45]; and HR, 1.42 [95% CI, 1.22–1.66]), but significantly lower in the treadmill test group (HR, 0.53 [95% CI, 0.42–0.67]; and HR, 0.69 [95% CI, 0.62–0.76]) compared with the CCTA group. After balancing baseline risk factors, there was no significant difference in the primary end point in those with single‐photon emission computed tomography (HR, 1.11 [95% CI, 0.78–1.57]; P =0.58) or treadmill test (HR, 0.84 [95% CI, 0.65–1.08]; P =0.18) groups, compared with the CCTA group. The event rate of the secondary end point was significantly lower in the treadmill test group than in the CCTA group (HR, 0.87 [95% CI, 0.78–0.96]; P =0.008). Conclusions: Compared with functional testing, initial CCTA was not associated with a lower rate of cardiac death or myocardial infarction when used as an initial diagnostic test for patients with suspected coronary syndromes.

31 December 2024 in The Korean Journal of Aerospace and Environmental Medicine
Verified
Journal Article
Open access
PDF file
WKWilliam D. Kim
William D. Kim
SKSang-Wook Kim
Sang-Wook Kim
SCSeong-Kyu Cho
Seong-Kyu Cho
JBJu Hyeon Byeon
Ju Hyeon Byeon
GLGunYoung Lee
GunYoung Lee
JJJoungSoon Jang
JoungSoon Jang
William D. Kim, M.D., Sang-Wook Kim, M.D., Ph.D., Seong-Kyu Cho, M.D., Ju Hyeon Byeon, B.S., GunYoung Lee, Ph.D., WooSeok Hyun, Ph.D., JoungSoon Jang, M.D., Ph.D.. Korean J Aerosp Environ Med 2024;34:101-7. https://doi.org/10.46246/KJAsEM.240023

1 January 2025 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
KHKyung Eun Ha
Kyung Eun Ha
WKWilliam D Kim
William D Kim
KKKyu-yong Ko
Kyu-yong Ko
HKHasung Kim
Hasung Kim
SGSeo-Yeon Gwak
Seo-Yeon Gwak
ICIksung Cho
Iksung Cho
Ha KE, et al. J Korean Med Sci. 2025 Jun;40:e183. https://doi.org/10.3346/jkms.2025.40.e183

1 January 2026 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
WKWilliam D. Kim
William D. Kim
JSJiwon Seo
Jiwon Seo
SLSeonhwa Lee
Seonhwa Lee
DKDae-Young Kim
Dae-Young Kim
HKHasung Kim
Hasung Kim
JHJi-won Hwang
Ji-won Hwang
Kim WD, et al. Yonsei Med J. 2025 Dec;66:e114. https://doi.org/10.3349/ymj.2025.0122